129 related articles for article (PubMed ID: 16505953)
1. Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency.
Villano JL; Mehta D; Radhakrishnan L
Invest New Drugs; 2006 Sep; 24(5):455-6. PubMed ID: 16505953
[No Abstract] [Full Text] [Related]
2. Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
Xie Y; Gong C; Zhang J; Wang L; Cao J; Tao Z; Li T; Zhao Y; Li Y; Hu S; Wang B; Hu X
BMC Cancer; 2021 Nov; 21(1):1174. PubMed ID: 34727875
[TBL] [Abstract][Full Text] [Related]
3. Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab.
Rahman HT; Yeh S; Bergstrom CS
J Ocul Pharmacol Ther; 2013 Apr; 29(3):360-2. PubMed ID: 23061416
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
5. [Clinical experience of nab-Paclitaxel treatment in 31 patients with breast cancer].
Tauchi Y; Kashiwagi S; Ishihara S; Asano Y; Sakimura C; Kurata K; Tokumoto M; Morisaki T; Noda S; Kawajiri H; Takashima T; Onoda N; Hirakawa K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1948-50. PubMed ID: 25731385
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications.
Kudlowitz D; Muggia F
Expert Opin Drug Saf; 2014 Jun; 13(6):681-5. PubMed ID: 24749649
[No Abstract] [Full Text] [Related]
7. [Administration of low-dose albumin-bound paclitaxel for the treatment of advanced and recurrent breast cancer patients].
Kawamura M; Nakano S; Kyoda S; Tabei I; Yoshida K; Takeyama H
Gan To Kagaku Ryoho; 2013 Jul; 40(7):909-12. PubMed ID: 23863734
[TBL] [Abstract][Full Text] [Related]
8. [Administration of nab-paclitaxel for 9 metastatic breast cancer patients].
Sakaguchi K; Mizuta N; Imai A; Nakatsukasa K; Morita M; Soushi M; Taguchi T
Gan To Kagaku Ryoho; 2012 Jul; 39(7):1081-5. PubMed ID: 22790043
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of supportive care for albumin-bound paclitaxel(nab-paclitaxel)in 20 patients with metastatic breast cancer].
Yamada C; Yonezawa M; Shimizu Y; Taga R; Kashihara H; Tsuji K; Murata T; Yoshino H
Gan To Kagaku Ryoho; 2014 Jan; 41(1):77-81. PubMed ID: 24423956
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.
Ciruelos E; Jackisch C
Expert Rev Anticancer Ther; 2014 May; 14(5):511-21. PubMed ID: 24575935
[TBL] [Abstract][Full Text] [Related]
11. Nab-paclitaxel-induced cystoid macular edema in a patient with pre-existing optic neuropathy.
Park E; Goldberg NR; Adams S
Anticancer Drugs; 2016 Jul; 27(6):580-4. PubMed ID: 26982237
[TBL] [Abstract][Full Text] [Related]
12. [Results of a drug use investigation of nanoparticle albumin-bound Paclitaxel for breast cancer].
Nakamura S; Iwata H; Funato Y; Ito K; Ito Y
Gan To Kagaku Ryoho; 2015 Apr; 42(4):447-55. PubMed ID: 25963691
[TBL] [Abstract][Full Text] [Related]
13. Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma.
Altundag K; Dede DS; Purnak T
J Clin Pathol; 2007 Aug; 60(8):958. PubMed ID: 17660346
[No Abstract] [Full Text] [Related]
14. [Efficacy and tolerability of controlled-release oxycodone against nab-paclitaxel-induced musculoskeletal pain in breast cancer patients].
Inoue K; Ohkubo F; Nagai S; Tsuboi M; Kubo K; Kurozumi K; Hayashi Y; Matsumoto H; Takei H
Gan To Kagaku Ryoho; 2013 Aug; 40(8):1021-5. PubMed ID: 23986044
[TBL] [Abstract][Full Text] [Related]
15. Albumin-bound paclitaxel (Abraxane) for advanced breast cancer.
Med Lett Drugs Ther; 2005 May; 47(1208):39-40. PubMed ID: 15880087
[TBL] [Abstract][Full Text] [Related]
16. [A case of secondary sclerosing cholangitis caused by chemotherapy with nab-paclitaxel].
Matsuo T; Nakamura Y; Suzuki K
Nihon Shokakibyo Gakkai Zasshi; 2015 May; 112(5):888-95. PubMed ID: 25947025
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
Gradishar WJ; Tjulandin S; Davidson N; Shaw H; Desai N; Bhar P; Hawkins M; O'Shaughnessy J
J Clin Oncol; 2005 Nov; 23(31):7794-803. PubMed ID: 16172456
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
19. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
[TBL] [Abstract][Full Text] [Related]
20. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
